2. Academic Validation
  3. Discovery of Clinical Candidate AZD0095, a Selective Inhibitor of Monocarboxylate Transporter 4 (MCT4) for Oncology

Discovery of Clinical Candidate AZD0095, a Selective Inhibitor of Monocarboxylate Transporter 4 (MCT4) for Oncology

  • J Med Chem. 2022 Dec 16. doi: 10.1021/acs.jmedchem.2c01342.
Frederick W Goldberg 1,  Jason G Kettle 1,  Gillian M Lamont 1,  David Buttar 2,  Attilla K T Ting 1,  Thomas M McGuire 1,  Calum R Cook 2,  David Beattie 1,  Pablo Morentin Gutierrez 1,  Stefan L Kavanagh 3,  Jasper C Komen 3,  Aarti Kawatkar 4,  Roger Clark 5,  Lorna Hopcroft 1,  Gareth Hughes 1,  Susan E Critchlow 1
Affiliations

Affiliations

  • 1 Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K.
  • 2 Pharmaceutical Sciences, AstraZeneca, Macclesfield SK10 2NA, U.K.
  • 3 Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge CB2 0AA, U.K.
  • 4 Discovery Sciences, AstraZeneca, Waltham, Massachusetts 02451, United States.
  • 5 Discovery Sciences, AstraZeneca, Cambridge CB2 0AA, U.K.
PMID: 36525250 DOI: 10.1021/acs.jmedchem.2c01342
Abstract

Due to increased reliance on glycolysis, which produces lactate, monocarboxylate transporters (MCTs) are often upregulated in Cancer. MCT4 is associated with the export of lactic acid from Cancer cells under hypoxia, so inhibition of MCT4 may lead to cytotoxic levels of intracellular lactate. In addition, tumor-derived lactate is known to be immunosuppressive, so MCT4 inhibition may be of interest for immuno-oncology. At the outset, no potent and selective MCT4 inhibitors had been reported, but a screen identified a triazolopyrimidine hit, with no close structural analogues. Minor modifications to the triazolopyrimidine were made, alongside design of a constrained linker and broad SAR exploration of the biaryl tail to improve potency, physical properties, PK, and hERG. The resulting clinical candidate 15 (AZD0095) has excellent potency (1.3 nM), MCT1 selectivity (>1000×), secondary pharmacology, clean mechanism of action, suitable properties for oral administration in the clinic, and good preclinical efficacy in combination with cediranib.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z